N
Nan Lin
Researcher at Harvard University
Publications - 1220
Citations - 65601
Nan Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 105, co-authored 687 publications receiving 54545 citations. Previous affiliations of Nan Lin include University of Michigan & Fujian Medical University.
Papers
More filters
Journal ArticleDOI
Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor.
Virginia C. Broudy,Franklin O. Smith,Nan Lin,Krisztina M. Zsebo,Joan C Egrie,Irwin D. Bernstein +5 more
TL;DR: It is indicated that SCF acts synergistically with IL-3 or GM-CSF to stimulate colony growth from the marrow cells of a portion of patients with AML.
Journal ArticleDOI
Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer
Nan Lin,Lisa A. Carey,Minetta C. Liu,Jerry Younger,Steven E. Come,Elizabeth Bullitt,A. D. Van Den Abbeele,Xiaochun Li,Fred H. Hochberg,EP Winer +9 more
TL;DR: Although the study failed to demonstrate the hypothesized level of activity as assessed by RECIST, there is sufficient evidence of clinical effect, albeit preliminary, to suggest that lapatinib can penetrate the CNS.
Journal ArticleDOI
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
Nan Lin,Eudocia Q. Lee,Hidefumi Aoyama,Igor J. Barani,Brigitta G. Baumert,Paul D. Brown,D. Ross Camidge,Susan M. Chang,Janet Dancey,Laurie E. Gaspar,Gordon J. Harris,F. Stephen Hodi,Steven N. Kalkanis,Kathleen R. Lamborn,Mark E. Linskey,David R. Macdonald,Kim Margolin,Minesh P. Mehta,David Schiff,Riccardo Soffietti,John H. Suh,Martin J. van den Bent,M.A. Vogelbaum,Jeffrey S. Wefel,Patrick Y. Wen +24 more
TL;DR: A critical review of trials specifically addressing brain metastases shows key issues that could prevent acceptance of results by regulatory agencies, including enrolment of heterogeneous groups of patients and varying definitions of clinical endpoints.
Journal ArticleDOI
Measuring depressive symptomatology in China.
TL;DR: A study was conducted on a representative sample of 1000 residents in Tianjin, China to construct a scale of depressive symptoms and proposed that a set of 22 items form the Chinese Depressive Symptom Scale (CDS-22) and that a subset of 16 items constitute the abbreviated version.
Journal ArticleDOI
Relationship between bispectral index values and volatile anesthetic concentrations during the maintenance phase of anesthesia in the B-Unaware trial
Elizabeth L. Whitlock,Alexander Villafranca,Nan Lin,Ben J.A. Palanca,Eric Jacobsohn,Kevin J. Finkel,Lini Zhang,Beth A. Burnside,Heiko Kaiser,Alex S. Evers,Michael S. Avidan +10 more
TL;DR: Independent of pharmacokinetic confounding, BIS frequently correlates poorly with end-tidal anesthetic concentrations, is often insensitive to clinically significant changes in ETAC, and is vulnerable to interindividual variability.